BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Phase 2
Terminated
- Conditions
- Acute Heart Failure
- Interventions
- Drug: Cinaciguat (BAY58-2667)Drug: Placebo
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5
- Registration Number
- NCT01067859
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
Phase 3
Completed
- Conditions
- Breast CancerDiagnostic Imaging
- Interventions
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 446
- Registration Number
- NCT01067976
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
Phase 2
Terminated
- Conditions
- Hypertension, PulmonaryVentricular Dysfunction, Left
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT01065051
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- Drug: BAY79-4620
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2
- Registration Number
- NCT01065623
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Phase 2
Terminated
- Conditions
- Acute Heart Failure
- Interventions
- Drug: Cinaciguat (BAY58-2667)Drug: Placebo
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01065077
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Phase 2
Active, not recruiting
- Conditions
- Hypertension, PulmonaryVentricular Dysfunction, Left
- Interventions
- Drug: PlaceboDrug: Riociguat (Adempas, BAY63-2521)
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 202
- Registration Number
- NCT01065454
Angeliq Regulatory Post Marketing Surveillance
Completed
- Conditions
- Postmenopausal PeriodOsteoporosis, Postmenopausal
- Interventions
- Drug: E2/DRSP (Angeliq, BAY86-4891)
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4078
- Registration Number
- NCT01064453
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
Phase 2
Terminated
- Conditions
- Heart FailureHeart Decompensation
- Interventions
- Drug: Cinaciguat (BAY58-2667)Drug: Placebo
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT01064037
Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine
Phase 3
Completed
- Conditions
- PharyngitisCommon Cold
- Interventions
- Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)Drug: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + PseudoephedrineDrug: PlaceboDrug: Pseudoephedrine
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1016
- Registration Number
- NCT01062360
Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 41
- Registration Number
- NCT01062282
© Copyright 2025. All Rights Reserved by MedPath